Incyte

Current directors and officers who also hold a role at another S&P 500 company.

• Suketu UpadhyayVRTX · DirectorZBH · CFO
• Otis W. BrawleyA · Director

Latest Schedule 13D/13G filing per holder. Holders that reported falling below 5% are not shown. Index funds usually report once a year.

No 5% holder filings parsed yet for this company.

Open-market purchases and sales reported on Form 4. Grants, option exercises and tax withholding are excluded.

Every 8-K with Item 5.02 (departure, election or appointment of directors and officers). The text is the first paragraph of the item.

1. Mar 30, 2026

   On March 26, 2026, Susanne Schaffert notified Incyte Corporation (the “Company”) that she was resigning from the Company’s Board of Directors (the “Board”), effective as of April 15, 2026. The resignation of Dr. Schaffert, who has been a member of the Company’s Board since 2022, was not the result of any disagreement with the Company on any matter relating to the Company’s operations, policies or practices. The Board thanks Dr. Schaffert for her thoughtful counsel and meaningful contributions to the Company during her service. 2

   Read the 8-K filing
2. Mar 26, 2026

   On March 25, 2026, Incyte Corporation (the “Company”) announced title changes for certain current members of its executive leadership team, effective immediately. Pablo J. Cagnoni’s title was changed to President, Incyte and Global Head of Research and Development; Steven H. Stein’s title was changed to Executive Vice President, Chief Medical Officer and Head of Late-stage Development; and Mohamed Issa’s title was changed to Executive Vice President and Head of U.S. Commercial. Dr. Cagnoni replaces William J. Meury as President, Incyte. Mr. Meury remains Chief Executive Officer and a member of the Company’s Board of Directors. Mr. Meury, Dr. Cagnoni, Dr. Stein and Dr. Issa are collectively referred to herein as the “Impacted Executives”. There were no changes to the compensation arrangements between the Company and any Impacted Executive in connection with these title changes.

   Read the 8-K filing
3. Dec 12, 2025

   Director Retirement On December 10, 2025, Hervé Hoppenot notified Incyte Corporation (the “Company”) that he was retiring from the Company’s Board of Directors, effective immediately. Mr. Hoppenot, the former Chairman and Chief Executive Officer of the Company, has been a member of the Company’s Board of Directors since 2014. 2

   Read the 8-K filing
4. Oct 3, 2025

   On September 30, 2025, the Board of Directors of Incyte Corporation (the “Company”) appointed Thomas Tray, the Company’s current Vice President, Finance and Chief Accounting Officer (principal accounting officer), to the additional position of principal financial officer, effective as of September 16, 2025. Mr. Tray, age 48, joined the Company in June 2005 as Manager, External Reporting, and has held roles of increasing responsibility, most recently prior to his current role as Vice President and Controller. Mr. Tray received his B.S. in Accounting from Mount Saint Mary’s University and has an Executive MBA in Pharmaceutical Marketing from Saint Joseph’s University. There are no arrangements or understandings between Mr. Tray and any other persons pursuant to which he was appointed as principal financial officer. Mr.

   Read the 8-K filing
5. Aug 7, 2025

   On August 4, 2025, Christiana Stamoulis, Executive Vice President and Chief Financial Officer of Incyte Corporation (the “Company”), notified the Company of her intent to step down from her role to pursue another opportunity, effective September 16, 2025. Ms. Stamoulis will remain at the Company until then to support a smooth transition. The Company has initiated the process of appointing a successor. 2

   Read the 8-K filing
6. Jun 27, 2025

   Retirement of President and Chief Executive Officer On June 26, 2025, Incyte Corporation (the “Company”) announced that Hervé Hoppenot retired as President and Chief Executive Officer of the Company effective June 26, 2025. Mr. Hoppenot will continue to serve as a member of the Company’s Board of Directors (the “Board”). Julian C. Baker, Lead Independent Director of the Board, assumed the role of Chairman of the Board effective June 26, 2025. In connection with his retirement, the Company and Mr. Hoppenot entered into a transition agreement (the “Transition Agreement”), dated as of June 26, 2025 (the “Effective Date”), pursuant to which Mr. Hoppenot will serve as special advisor to the Company’s Chief Executive Officer and will provide advice and counsel in connection with the Chief Executive Officer transition as may be reasonably requested by the Chief Executive Officer or the Board.

   Read the 8-K filing
7. Jun 11, 2025

   2010 Amended and Restated Stock Incentive Plan Amendment At the Annual Meeting of Stockholders of Incyte Corporation (the “Company”) held on June 10, 2025 (the “Annual Meeting”), the stockholders of the Company approved the following amendment to the Company’s Amended and Restated 2010 Stock Incentive Plan (the “SIP”): (i) an increase in the number of shares available for issuance under the SIP by 8,500,000 shares, from 66,453,475 shares to 74,953,475 shares, (ii) removal of the fungible share ratio for future awards, and (iii) extension of the termination date of the SIP by five years. A copy of the SIP, as amended on April 11, 2025, and including the amendments approved by the stockholders, is attached hereto as Exhibit 10.1 and incorporated herein by reference.

   Read the 8-K filing
8. Jan 10, 2025

   On January 6, 2025, Barry P. Flannelly, Executive Vice President, General Manager, North America of Incyte Corporation (the “Company”), announced his retirement from the Company and stepped down from that role on that date, effective with the commencement of employment of his successor. Dr. Flannelly will remain employed by the Company through July 31, 2025 to assist with the transition of his responsibilities. 2

   Read the 8-K filing
9. Sep 12, 2023

   On September 8, 2023, Maria E. Pasquale, Executive Vice President, General Counsel and Corporate Secretary of Incyte Corporation (the “Company”), notified the Company of her intention to retire effective November 1, 2023. Ms. Pasquale’s roles as Executive Vice President, General Counsel and Corporate Secretary of the Company may end earlier than her retirement date to the extent her successor is appointed to and assumes those roles prior to that date, and in such event Ms. Pasquale will remain employed through her retirement date to assist with the transition of her responsibilities. 2

   Read the 8-K filing
10. Jun 15, 2023

    2010 Amended and Restated Stock Incentive Plan Amendment At the Annual Meeting of Stockholders of Incyte Corporation (the “Company”) held on June 14, 2023 (the “Annual Meeting”), the stockholders of the Company approved the following amendment to the Company’s Amended and Restated 2010 Stock Incentive Plan (the “SIP”): an increase in the number of shares available for issuance under the SIP by 12,500,000 shares, from 53,953,475 shares to 66,453,475 shares. A copy of the SIP, as amended on April 13, 2023, and including the amendment approved by the stockholders, is attached hereto as Exhibit 10.1 and incorporated herein by reference.

    Read the 8-K filing
11. Oct 4, 2022

    Election of Directors Effective October 1, 2022, the Board of Directors of Incyte Corporation (the “Company”) increased the number of authorized members of the Board of Directors of the Company to nine and elected Susanne Schaffert, Ph.D., a member of the Board of Directors of the Company. Dr. Schaffert, age 55, previously spent 26 years at the pharmaceutical company Novartis AG, where she served in various roles. Most recently Dr. Schaffert served as President of Novartis Oncology from January 2019 until April 2022. Prior to that role, Dr. Schaffert served from January 2018 to February 2019 as President and Chair of Accelerated Advanced Applications and from December 2012 to January 2018 as General Manager Region Europe, Novartis Oncology. From March 2010 to December 2012, Dr. Schaffert was Global Head of Investor Relations, and before that, Dr.

    Read the 8-K filing
12. Apr 21, 2022

    Director Retirement On April 18, 2022, Wendy L. Dixon notified Incyte Corporation (the “Company”) that she will be retiring from the Company’s Board of Directors, effective at the time of the Company’s 2022 Annual Meeting of Stockholders. Dr. Dixon has been a member of the Company’s Board of Directors since 2010. 2

    Read the 8-K filing
13. Jan 14, 2022

    On January 10, 2022, Paul Trower notified Incyte Corporation (the “Company”) of his intention to retire as Division Vice President, Finance and Principal Accounting Officer of the Company effective March 11, 2022. Effective March 11, 2022, the board of directors of the Company appointed Thomas Tray, age 44, as the Company’s Vice President, Finance and Chief Accounting Officer (Principal Accounting Officer). Mr. Tray joined the Company in June 2005 as Manager, External Reporting, and has held roles of increasing responsibility, most recently as Vice President and Controller. Mr. Tray began his career in the audit practice of PricewaterhouseCoopers LLP where he held several positions of increasing responsibility from August 1999 through May 2005. Mr. Tray received his B.S.

    Read the 8-K filing
14. Sep 28, 2021

    Election of Directors Effective September 27, 2021, the Board of Directors of Incyte Corporation (the “Company”) increased the number of authorized members of the Board of Directors of the Company to nine and elected Otis W. Brawley, M.D., a member of the Board of Directors of the Company. Dr. Brawley, age 62, has served as a Bloomberg Distinguished Professor of Oncology and Epidemiology at Johns Hopkins University since January 2019. From April 2007 to December 2018, Dr. Brawley served as the Chief Medical and Scientific Officer of the American Cancer Society. From January 2002 to August 2007, Dr. Brawley was director of the Georgia Cancer Center at Grady Memorial Hospital. From April 2001 to December 2018, Dr. Brawley served as professor of hematology, oncology, medicine and epidemiology at Emory University. Prior to joining Emory University, Dr.

    Read the 8-K filing
15. May 27, 2021

    2010 Amended and Restated Stock Incentive Plan Amendments At the Annual Meeting of Stockholders of Incyte Corporation (the “Company”) held on May 26, 2021 (the “Annual Meeting”), the stockholders of the Company approved the following amendments to the Company’s Amended and Restated 2010 Stock Incentive Plan (the “Plan”): (a) an increase in the number of shares available for issuance under the Plan by 9,500,000 shares, from 44,453,475 shares to 53,953,475 shares, (b) extend the termination date of the Plan from June 30, 2021 to June 30, 2026 and (c) change the automatic grants of equity awards to outside (non-employee and non-consultant) directors to provide that such directors will receive annual grants with an aggregate grant date fair value to be determined at the discretion of the Company’s board of directors, provided that such value does not exceed $500,000, and to change the mix of…

    Read the 8-K filing

Proxy statements (DEF 14A): 2026 · 2025 · 2024 · 2023 · 2022 · 2021

From the company's 10-K XBRL data (SEC companyfacts).

People who stopped filing as an insider of this company. “Last filing” is the last Form 3/4/5, an upper bound on when they left.